연구동향 분석
박사

Development of Solid Lipid Nanoparticles and Their Applications to Medicine : 고형 지질 나노입자의 개발 및 의학적 적용에 관한 연구

김진호 2015년

논문상세정보
인용/피인용
' Development of Solid Lipid Nanoparticles and Their Applications to Medicine : 고형 지질 나노입자의 개발 및 의학적 적용에 관한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • sirna 전달 나노입자
  • 고형 지질 나노입자
  • 나노메디신
  • 나노입자
  • 심혈관 질환 치료 나노입자
  • 암 치료 나노입자
  • 약물 전달 시스템
  • 양이온성
  • 유사
  • 저밀도
  • 지단백질
  • 표적 지향형 약물 전달체
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
149 0

0.0%

' Development of Solid Lipid Nanoparticles and Their Applications to Medicine : 고형 지질 나노입자의 개발 및 의학적 적용에 관한 연구' 의 참고문헌

  • http://www.laserpartner.cz/lasp/web/en/2000/0015.htm (Accessed on May 25, 2009).
  • Zhdanov, R. I., Podobed, O. V., Vlassov, V. V. Cationic lipid-DNA complexes-lipoplexes-for gene transfer and therapy. Bioelectrochemistry 2002, 58, 53-64.
  • Zhang, X. et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusioninduced lung apoptosis. J. Biol. Chem. 2004, 279, 10677-10684.
  • Zamanian-Daryoush, M., et al. Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J. Interferon Cytokine Res. 2008, 28, 221-233.
  • Yuan, F., Dellian, M., Fukumura, D., et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55, 3752-3756.
  • You, J., Zhang, G., Li, C.Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-ingrared light-triggered drug release. ACS Nano 2010, 4, 1033-1041.
  • Yoo, J. W., Irvine, D. J., Discher, D. E., Mitragotri, S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nature reviews. Drug discovery 2011, 10, 521-535.
  • Yoo, H.S., Kwon, S.M., Kim, Y.J., Chung, H., Kwon, I.C., Kim, J., Jeong, S.Y. Cationic lipid emulsions containing heavy oils for the transfection of adherent cells. J. Controlled Release 2004, 98, 179-188.
  • Yi, S W., Yune, T.Y., Kim, T.W., Chung, H., Choi, Y.W., Kwon, I.C., Lee, E.B., Jeong, S.Y. A cationic lipid emulsion/DNA complex as a physically stable and serum-resistant gene delivery system. Pharm. Res. 2000, 17, 314-320.
  • Yang, J., Lee, C.H., Ko, H.J., Suh, J.S., Yoon, H.G., Lee, K., Huh, Y.M., Haam, S. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew. Chem. Int. Ed. 2007, 46, 8836-8839.
  • Xing, X., Yujiao Chang, J., Hung, M. Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. AdV. Drug Delivery ReV. 1998, 30, 219-227.
  • Wisse, E., Braet, F., Luo, D., et al. Structure and function of sinusoidal lining cells in the liver. Toxicol. Pathol. 1996, 24, 100-111.
  • Weiss, R.B., Donehower, R.C., Wiernik, P H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker, J.R., Van Echo, D.A.; Von Hoff, D.D.; Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8, 1263-1268.
  • Wasan, K.M., Cassidy, S.M. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 1998, 87, 411423.
  • Wang, H., Zhao, Y., Wu, Y., Hu, Y.L., Nan, K., Nie, G., Chen, H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32, 8281-8290.
  • Wang, A.Z., Langer, R., Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu. Rev.Med. 2012, 63, 185-198.
  • Templeton, N. S., Lasic, D. D., Frederik, P. M., Strey, H. H., Roberts, D. D., Pavlaki, G. N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 1997, 15, 647-652.
  • Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432, 173-178.
  • Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Med. 2003, 9, 347-351.
  • Singla, A.K., Garg, A., Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm. 2002, 235, 179-192.
  • Siekmann B., Westesen K., Submicron-sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1992, 3, 123-126.
  • Scherr, M., Battmer, K., Dallmann, I., Ganser, A., Eder, M. Inhibition of GM-CSF receptor function by stable RNA interference in a NOD/SCID mouse hematopoietic stem cell transplantation model. Oligonucleotides 2003, 13, 353-363.
  • Scheffel U., Rhodes B.A., Natajaran T.K., Wagner H.N. Albumin microspheres for study of the reticuloendothelial system. J. Nucl. Med. 1970, 13, 498-503.
  • Sabnis, N., Lacko, A.G. Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics. Ther. Deliv. 2012, 3, 599608.
  • Rowinsky, E.K. Clinical pharmacology of Taxol. J. Natl. Cancer Inst. Monogr. 1993, 15, 25-37.
  • Ross, J.S., Schenkein, D.P., Pietrusko, R., et al. Targeted therapies for cancer. Am. J. Clin. Pathol. 2004, 122, 598-609.
  • Reich, S.J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 2003, 9, 210-216.
  • Prassl, R., Pregetter, M., Amenitsch, H., Kriechbaum, M., Schwarzenbacher, R., Chapman, J.M., Laggner, P. Low density lipoproteins as circulating fast temperature sensors. PloS one 2008, 3, e4079.
  • Perrault, S.D., Walkey, C., Jennings, T., Fischer, H.C., Chan, W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009, 9, 1909-1915.
  • Park, J.W., Hong, K., Kirpotin, D.B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U.B., Marks, J.D., Moore, D., Papahadjopoulos, D., Benz, C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002, 8, 1172-1181.
  • Park, H., Yang, J., Lee, J., Haam, S., Choi, I.H., Yoo, K.H. Multifunctional nanoparticles for combined doxorubicin and photothermal treatments. ACS Nano 2009, 3, 2919-2926.
  • Ntziachristos, V., Tung, C.H., Bremer, C., Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo.Nature Med. 2002, 8, 757-760.
  • Novina, C.D., Sharp, P.A. The RNAi revolution. Nature 2004, 430, 161-164.
  • Muller R.H., Runge S.A. Solid lipid nanoparticles (SLN?) for controlled drug delivery. In: Benita S. (ed.) Submicron Emulsions in Drug Targeting and Delivery. Amsterdam: CRC Press; 1998. 219-234.
  • Morgillo, F., Lee, H.Y. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 2005, 8, 298-310.
  • Mok, J., Lee, S.H., Park, J.W., Park, T.G. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing. Nat. Mater. 2010, 9, 272-278.
  • Moghimi, S.M., Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42, 463-478.
  • Moghimi, S.M., Hunter, A.C., Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53, 283-318.
  • Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
  • Lucks S., Muller R., WIPO Patent No. 1993005768. Geneva, Switzerland: World Intellectual Property Organization, http://patentscope.wipo.int/search/en/WO1993005768 (accessed 14 October 2013).
  • Lee, K.S., Chung, H.C., Im, S.A., Park, Y.H., Kim, C.S., Kim, S.B., Rha, S.Y., Lee, M.Y., Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. 2008, 108, 241-250.
  • Lee, H., Mok, H., Lee, S., Ph, Y., Park, T.G. Target specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J. Controlled Release 2007, 119, 245-252.
  • Lee, A.L., Wang, Y., Cheng, H.Y., Pervaiz, S., Yang, Y.Y. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30, 919-927.
  • Kirpotin, D.B., Drummond, D.C., Shao, Y., Shalaby, M.R., Hong, K., Nielsen, U.B., Marks, J.D., Benz, C.C., Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66, 6732-6740.
  • Kim., S.H., Jeong, J.H., Lee, S.H., Kim, S.W., Park, T.G. LHRH receptor-mediated delivery of siRNA using polyelectrolyte and PEI. Bioconjugate Chem. 2008, 19, 2156-2162.
  • Kim, Y.J., Kim, T.W., Chung, H., Kwon, I.C., Sung, H.C., Jeong, S.Y. The effects of serum on the stability and the transfection activity of the cationic lipid emulsion with various oils. Int. J. Pharm. 2003, 252, 241-252.
  • Kim, S.H., Jeong, J.H., Lee, S.H., Kim, S.W., Park, T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Controlled Release 2006, 116, 123-129.
  • Kim, S.C., Kim, D.W., Shim, Y.H., Bang, J.S., Oh, H S., Wan Kim, S., Seo, M.H. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Controlled Release 2001, 72, 191-202.
  • Kim, J., Kim, Y., Bae, K.H., Park, T.G., Lee, J.H., Park, K.Tumor-targeted delivery of paclitaxel using low density lipoprotein-mimetic solid lipid nanoparticle. Mol. Pharm. 2015, 12, 1230-1241.
  • Kim, J. S., Maruyama, A., Akaike, T., Kim, S. W. Terplex DNA delivery system as a gene carrier. Pharm. Res. 1998, 15, 116-121.
  • Kim, H.R., Kim, I.K., Bae, K.H., Lee, S.H., Lee, Y., Park, T.G. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 2008, 5, 622-631.
  • Kebbekus, P., Draper, D.E., Hagerman, P. Persistance Length of RNA. Biochemistry 1995, 34, 4354-4357.
  • Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y,; Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., Matsumura, Y., Ikeda, R. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 2012, 30, 1621-1627.
  • Jung, H.S., Kong, W., Sung, D.K., Lee, M., Beack, S.E., Keum, D.H., Kim, K.S., Yun, S.H., Hahn, S.K. Nanographene OxideHyaluronic Acid Conjugate for Photothermal Ablation Therapy of Skin Cancer, ACS Nano 2014, 8, 260-268.
  • Joshi, A., Punyani, S., Bale, S.S., Yang, H.T., Kane, R.S. Nanotube-assisted protein deactivation. Nat. Nanotechnol. 2008, 3, 41-45.
  • Jain, R.K., Stylianopoulos, T., Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7, 653-664.
  • Huang, X.I., El-Sayed, H., Qian,W., El-Sayed, M.A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 2006, 128, 2115-2120.
  • Hrkach, J., Von Hoff, D., Mukkaram Ali, M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J. J.; Song, Y. H. Summa, J.; Tompsett, D.; Troiano, G., Van Geen Hoven, T., Wright, J., LoRusso, P., Kantoff, P.W., Bander, N.H., Sweeney, C., Farokhzad, O.C., Langer, R., Zale, S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4, 128ra39.
  • Hirsch, L.R.R., Stafford, J.J., Bankson, A., Sershen, R.B., Rivera, R.E., Price, J.D., Hazle, N.J., Halas, J.L. Proc. Natl. Acad. Sci. USA 2003, 100, 13549-13554.
  • Hauck, H., Yang, J., Lee,J., Haam, S., Choi, I.H., Yoo, K.H. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv. Mater. 2008, 20, 3832-3838.
  • Harris, J.M., Martin, N.E., Modi, M. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 2001, 40, 539-551.
  • Green, M. R., Manikhas, G.M., Orlov, S., Afanasyev, B., Makhson, A.M., Bhar, P., Hawkins, M.J. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 17, 1263-1268.
  • Glueck, C.J., et al. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. Metabolism 1997, 46, 625-633.
  • Ginsburg, G. S., Small, D. M., Atkinson, D. Microemulsions of phospholipids and cholesterol esters. Protein-free models of low density lipoprotein. J. Biol. Chem. 1982, 257, 8216-8227.
  • Gianni, L., Kearns, C.M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., Egorin, M.J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 1995, 13, 180-190.
  • Gelderblom, H., Verweij, J., Nooter, K., Sparreboom, A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 2001, 37, 1590-1598.
  • Gary, D.J., Puri, N.,Won, Y.Y. Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Controlled Release 2007, 121, 64-73.
  • Ferrari, M. Nanotechnology-enabled medicine. Discov. Med. 2005, 5, 363-366.
  • Farhood, H., Serbina, N.,Huang, L. The role of dioleoyl phosphatidyl ethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1995, 1235, 289-295.
  • Elmen, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Orum, H., Koch, T., Wahlestedt, C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005, 33, 439-447.
  • Eldem T., Speiser P., Hincal A. Optimization of spray-dried and-congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharmaceutical research 1991, 8, 47-54.
  • Dorn, G. et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004, 32, e49.
  • Djojosubroto, M.W., Choi, Y.S., Lee, H.W., Rudolph, K.L. Telomeres and telomerase in aging, regeneration and cancer. Mol. Cell 2003, 15, 164-75.
  • Devalapally, H., Chakilam, A., Amiji, M.M. Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci. 2007, 96, 2547-2565.
  • Deckelbaum, R. J., Shipley, G. G., Small, D.M. Structure and interactions of lipids in human plasma low density lipoproteins. The Journal of biological chemistry 1977, 252, 744-754.
  • De Paula, D., Bentley, M.V., Mahato, R.I. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007, 13, 431-456.
  • Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
  • Danhie,r F., Feron, O., Preat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148, 135-46.
  • Ciani, L., Ristori, S., Salvati, A., Calamai, L., Martini, G. DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery: zeta potential measurements and electron spin resonance spectra. Biochim. Biophys. Acta 2004, 1664, 70-79.
  • Chung, N.S., Wasan, K.M. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv. Drug Deliv. Rev. 2004, 56, 13151334.
  • Cheng, J., Teply, B.A., Sherifi, I., Sung, J., Luther, G., Gu, F.X., Levy-Nissenbaum, E., Radovic-Moreno, A.F., Langer, R., Farokhzad, O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28, 869-876.
  • Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
  • Burnett, J.R., Barrett, P.H., Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies. Crit. Rev. Clin. Lab. Sci. 2002, 39, 89-137.
  • Bull, D. A., Bailey, S. H., Rentz, J. J., Zebrack, J. S., Lee, M., Litwin, S. E., Kim, S. W. Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction. VEGF gene therapy for myocardial infarction. J. Controlled Release 2003, 93, 175-181.
  • Brown, M.S., Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232, 34-47.
  • Boggs, J. M., Hsia, J. C. Effect of cholesterol and water on the rigidity and order of phosphatidylcholine bilayers. Biochim. Biophys. Acta 1972, 290, 32-42.
  • Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A., Davis, M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549-15554.
  • Akin, A., Michael,G., June, Q., Daniel, G.A., et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol. Ther. 2009, 5,8725-879.
  • Affleck, D. G., Yu, L., Bull, D. A., Bailey, S. H.,Kim, S. W. Augmentation of myocardial transfection using TerplexDNA: a novel gene delivery system. Gene Ther. 2001, 8, 349-353.
  • Adams, M.L., Lavasanifar, A., Kwon, G.S. Amphiphilic block copolymers for drug delivery. J. Pharm. Sci.2003, 92, 1343-1355.